Jefferies upgrades GE HealthCare to 'buy,' sets PT at $103

Published 09/01/2025, 01:08 am
© Reuters
GEHC
-

Investing.com -- Jefferies analysts recently upgraded their rating on GE HealthCare (NASDAQ:GEHC) Technologies Inc. to "buy" from "hold," reflecting a more optimistic outlook for the company. 

Shares of the medical technology company were up 1.3% in pre-open trade at 09:04 ET (14:04 GMT).

The upgrade comes with a revised price target of $103, up from the previous $95, citing factors such as market positioning, growth opportunities, and new product launches as drivers for the anticipated stock performance.

GE HealthCare operates in key areas like imaging, advanced visualization, patient care solutions, and pharmaceutical diagnostics. 

In particular, analysts noted the company's potential to capture market share in diagnostic imaging and prenatal diagnosis, which they described as expanding and under-modeled for future growth. 

Products such as Flyrcado, a cardiac PET agent, and others like Vizamyl and Cerianna, are positioned to support revenue increases, especially as new diagnostics become more integrated into healthcare systems.

Jefferies also pointed to strong execution in a healthy market environment, with the company's current trading multiple seen as undervalued compared to historical averages and peers. 

The analysts said that GE HealthCare's recurring revenues, which constituted 45% of total sales in 2023, are expected to rise to about 60% over the long term. 

This shift, coupled with mid-term opportunities in China and ongoing innovation in imaging and digital healthcare, adds to the optimism around the company's future.

Additionally, GE HealthCare’s investor day presentation in late 2024 outlined medium-term targets for 4-6% organic revenue growth and an increase in EBIT margins to 20% or higher by 2028. 

These conservative goals, combined with ongoing cost optimizations and strategic pricing initiatives, suggest further upside potential.

“We see GEHC as a structural winner in imaging alongside SHL (Julien Dormois, Buy) given we expect these players to lead on innovation and benefit from consolidation,” Jefferies said. 

They cited China’s delayed stimulus as an area of uncertainty but added that any recovery in this market would be an additional boost for the company.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.